U.S. Life Sciences Stock News

Forgent Power Solutions (NYSE:FPS) has launched a major follow on equity offering, aiming to raise fresh capital for the business. The company has also repriced its senior credit facilities, which is expected to materially reduce annual interest expenses. Together, these moves mark a clear shift in Forgent Power Solutions capital structure and financial flexibility. Forgent Power Solutions comes into this financing reset with the stock at $47.3 and strong recent momentum, up 5.7% over the...

Webco Industries (OTCPK:WEBC) has put up a punchy Q3 2026 print, with revenue of US$179.6 million, basic EPS of US$12.28 and trailing 12 month EPS of US$30.18 helping to lift trailing net profit margin to 3.1% from 1.2% a year earlier and earnings up 177.9% over the last year. The company has seen quarterly revenue move from US$155.4 million in Q3 2025 to US$179.6 million in Q3 2026, while quarterly EPS shifted from US$7.54 to US$12.28 over the same period. This sets up a results season in...

Latest FY 2026 earnings snapshot Mesa Laboratories (MLAB) just closed FY 2026 with fourth quarter revenue of US$63.7 million and a loss per share of US$0.75, as net income excluding extra items came in at a loss of US$4.1 million. Over the past year the company has seen quarterly revenue move from US$62.1 million in FY 2025 Q4 to US$63.7 million in FY 2026 Q4, while quarterly EPS has swung between a loss of US$1.31 and a profit of up to US$0.87. This combination of improving trailing...

Movado Group (MOV) just posted Q1 2027 results with revenue of US$142.4 million and basic EPS of US$0.30, compared with trailing twelve month revenue of US$681.9 million and EPS of US$1.44 that delivered year-over-year earnings growth of 80.4%. Over the last year, revenue has been broadly steady at 0.4% growth while net profit margin moved from 2.7% to 4.7%. This sets up this quarter as part of a wider shift in the earnings profile. For investors, that margin progression, combined with the...

Abercrombie & Fitch (ANF) opened Q1 2027 with revenue of US$1.1b and basic EPS of US$1.49, alongside net income of US$67.1m for the quarter. The company recorded quarterly revenue of US$1.10b in Q1 2026 and US$1.11b in Q1 2027, while basic EPS moved from US$1.63 to US$1.49 over the same period. This presents a picture in which investors are weighing solid top line scale against more mixed per share outcomes. With trailing net margin coming in lower than the prior year in the provided data,...

Semtech (SMTC) opened Q1 2027 with revenue of about US$291 million, basic EPS of roughly US$0.29 and net income of around US$26.6 million, providing a clear snapshot of its latest quarterly performance. The company reported revenue of about US$251.1 million in Q1 2026 and roughly US$291 million in Q1 2027, while basic EPS moved from about US$0.22 to roughly US$0.29 over the same period. This offers investors a direct view of how the top and bottom line compare year on year. Overall, margins...

Wondering if Astec Industries at about US$51 per share is offering fair value right now, or if the recent price puts you at risk of overpaying? The stock is up 4.9% over the last 7 days and 14.4% year to date, although it is down 13.1% over the past month, with a 31.0% return over the last year and 44.0% over three years, while the five-year return shows a decline of 20.8%. Recent headlines around infrastructure spending, construction activity and heavy equipment demand have kept attention...

Insulet (NasdaqGS:PODD) issued a voluntary recall and medical device correction for certain Omnipod insulin Pods due to a manufacturing defect that can cause insulin under delivery. The action affects roughly 7 million Pods globally across the Omnipod 5, DASH, and Eros product lines. Insulet has received multiple reports of serious adverse events, including at least 24 severe cases requiring hospitalization, but no fatalities. The company is replacing affected Pods at no cost and does not...

Corbus Pharmaceuticals reported updated Phase 1/2 data for its Nectin-4 antibody‑drug conjugate CRB-701, showing robust activity and manageable safety in HPV‑driven oropharyngeal and cervical cancers, with plans to present the results at the ASCO 2026 meeting and to launch registrational trials in both indications. An interesting development is the FDA’s broad alignment on registrational trial designs targeting accelerated approval in second‑line oropharyngeal squamous cell carcinoma and...

NextEra Energy and Dominion Energy (NYSE:D) have announced a definitive all stock agreement. The transaction would create the largest utility company in the U.S. if completed. The combined company is expected to operate with dual headquarters and a shared leadership structure. The deal would broaden reach across key power markets serving data centers and electrification trends. Dominion Energy enters this merger process with its shares at $67.2 and a return of 25.8% over the past year,...

Monro (MNRO) closed FY 2026 with fourth quarter revenue of US$273.8 million and a reported loss of US$6.6 million, equal to EPS of US$0.22, against a trailing twelve month profit of US$2.2 million and EPS of US$0.07 on revenue of US$1.2 billion. Over recent quarters the company has seen revenue move between US$305.8 million in Q3 FY 2025, US$301.0 million in Q1 FY 2026, US$288.9 million in Q2, US$293.4 million in Q3 and US$273.8 million in Q4. EPS has swung from a loss of US$0.72 in Q4 FY...

Milk-Bone, owned by J. M. Smucker, has launched limited-edition Krypto Soft & Chewy Mini Treats. The release is tied to Warner Bros.' upcoming Supergirl film, expanding Milk-Bone's branded collaborations. The partnership is aimed at boosting brand visibility and engaging pet owners through an entertainment tie-in. For investors watching J. M. Smucker (NYSE:SJM), this Milk-Bone and Warner Bros. collaboration adds a fresh marketing angle to the pet treats portfolio. The stock recently closed...

Wondering whether Appian stock is offering value at its current price, or whether the risks outweigh the potential reward. The share price closed at US$21.64, with a small 1.4% gain over the last week and declines of 1.5% over the last month, 36.5% year to date and 30.7% over the past year. These moves may have shifted how investors view its risk and return profile. These moves sit against a backdrop of ongoing interest in low code and automation platforms. Investors are weighing long term...

Abbott Laboratories (NYSE:ABT) secured US and European clearance for its Ultreon 3.0 AI-powered coronary imaging platform, aimed at improving decision support during stent placement. The company received CE Mark in Europe for Libre Duo, a dual continuous glucose-ketone sensor designed for more comprehensive diabetes management. Abbott plans to present new evidence on its cancer diagnostics portfolio at the ASCO Annual Meeting, focusing on early detection and treatment guidance. Updated...

Kingsoft Cloud Holdings (NasdaqGS:KC) opened Q1 2026 with revenue of C¥2.7b and a basic EPS loss of C¥1.13. Trailing twelve month figures show revenue of C¥10.3b and a cumulative EPS loss of C¥3.36. Over recent quarters the company has reported revenue of C¥2.2b in Q4 2024, C¥2.0b in Q1 2025 and C¥2.7b in Q1 2026. Quarterly EPS losses ranged from C¥0.80 in Q4 2024 to C¥1.71 in Q2 2025 and C¥1.13 in the latest quarter, highlighting how efficiently revenue may eventually translate into...

Capri Holdings (CPRI) just wrapped FY 2026 with Q4 revenue of US$796 million and a small loss, with basic EPS coming in at US$0.01, while on a trailing twelve month basis EPS was US$0.66 on revenue of US$3.5 billion. Over the past few quarters, revenue has moved between US$797 million and US$1.0 billion, with quarterly EPS ranging from a loss of US$0.28 to a profit of US$0.48, giving investors a mixed but improving read on profitability. Overall, the latest print points to tight margins and...

Many investors are considering whether Albemarle's current share price fairly reflects its potential, or if the stock might be mispriced. The stock recently closed at US$177.47, with a 4.3% gain over the past 7 days, a decline of 11.1% over the past 30 days, and returns of 23.3% year to date and 211.1% over the last year. Recent headlines around Albemarle have kept attention on the stock, and investors are closely watching how broader sentiment toward materials and battery related companies...

Meta Platforms is reported to have pulled back from bidding on key non-IDFA iOS mobile ad inventory. This change directly affects a core segment of AppLovin's AXON AI ad platform business. The shift gives AppLovin (NasdaqGS:APP) more room to compete for this traffic without head-to-head bidding from Meta. AppLovin runs a large mobile advertising and app monetization platform, with AXON AI focused on matching ads to users across iOS and other ecosystems. With a major competitor stepping back...

Virtuix secured funding from the United States Air Force to advance its AI-powered VR battlefield rehearsal platform.

Royalty Pharma recently reported strong first-quarter 2026 results, highlighting double-digit growth in portfolio and royalty receipts and continued expansion of its more than 35 marketed therapies and 20 development-stage assets. At the same time, the company has been drawing increased investor interest as a major buyer of biopharmaceutical royalties, using collaborations in areas such as oncology, rare disease and neuroscience to reinforce confidence in its long-term cash flow...

Modine Manufacturing (MOD) just closed out FY 2026 with Q4 revenue of US$954.4 million and basic EPS of US$1.36, alongside trailing 12 month revenue of US$3.2 billion and EPS of US$2.26. These results reflect a year shaped by both solid quarterly profits and a large one off loss. Over recent periods, the company has seen quarterly revenue move from US$647.2 million with EPS of US$0.92 in FY 2025 Q4 to FY 2026 quarterly figures ranging between US$682.8 million and US$954.4 million. Over the...

Veradigm (MDRX) has just put fresh numbers on the table for FY 2024, with trailing 12 month revenue of US$594.4 million and a reported loss of US$291.5 million, alongside basic EPS of US$2.7 in the red. This sets a clear backdrop of revenue scale paired with negative earnings. The company has seen trailing revenue hold in a tight band between US$588.0 million and US$625.9 million over recent periods, while net income swung from a profit of US$49.2 million to a loss of US$291.5 million. This...

Hippocratic AI has reached 10 million patient calls on DigitalOcean’s AI-Native Cloud, in collaboration with NVIDIA. The milestone comes from production use in healthcare, a sector that relies on high reliability and safety. The partnership gives DigitalOcean Holdings (NYSE:DOCN) direct exposure to real world AI workloads beyond test or pilot projects. For investors tracking NYSE:DOCN, this healthcare milestone sits at the intersection of cloud infrastructure and applied AI. DigitalOcean is...

Amdocs (DOX) Q2 2026 earnings: steady top line, softer EPS, and a margins story investors will focus on Amdocs (DOX) has reported Q2 2026 revenue of US$1,172 million and basic EPS of US$1.29, with the stock trading around US$61.29 as investors weigh the latest set of numbers. The company has seen quarterly revenue move from US$1,110 million in Q1 2025 to US$1,172 million in Q2 2026, while basic EPS has ranged from US$1.34 to US$1.46 in early 2025 to US$1.29 this quarter, setting a clear track...